EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat

Sebastian Frechen iD, Ibrahim Ince, André Dallmann iD, Michael Gerisch iD, Natalia A Jungmann, Corina Becker, Maximilian Lobmeyer, Maria E Trujillo, Shiyao Xu, Rolf Burghaus iD, Michaela Meyer

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Sebastian Frechen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany. Hauptthemen laut MEDLINE: Mefenamic Acid, Glucuronosyltransferase, Heterocyclic Compounds, 2-Ring, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vericiguat (Verquvo; US: Merck, other countries: Bayer) is a novel drug for the treatment of chronic heart failure. Preclinical studies have demonstrated that the primary route of metabolism for vericiguat is glucuronidation, mainly catalyzed by uridine diphosphate‐glucuronosyltransferase (UGT)1A9 and to a lesser extent UGT1A1. Whereas a drug–drug interaction (DDI) study of the UGT1A9 inhibitor mefenamic acid showed a 20% exposure increase, the effect of UGT1A1 inhibitors has not been assessed clinically. This modeling study describes a physiologically‐based pharmacokinetic (PBPK) approach to complement the clinical DDI liability assessment and support prescription labeling. A PBPK model of vericiguat was developed based on in vitro and clinical data, verified against data from the mefenamic acid DDI study, and applied to assess the UGT1A1 DDI liability by running an in silico DDI study with the UGT1A1 inhibitor atazanavir. A minor effect with an area under the plasma concentration‐time curve (AUC) ratio of 1.12 and a peak plasma concentration ratio of 1.04 was predicted, which indicates that there is no clinically relevant DDI interaction anticipated. Additionally, the effect of potential genetic polymorphisms of UGT1A1 and UGT1A9 was evaluated, which showed that an average modest increase of up to 1.7‐fold in AUC may be expected in the case of concomitantly reduced UGT1A1 and UGT1A9 activity for subpopulations expressing non‐wild‐type variants for both isoforms. This study is a first cornerstone to qualify the PK‐Sim platform for use of UGT‐mediated DDI predictions, including PBPK models of perpetrators, such as mefenamic acid and atazanavir, and sensitive UGT substrates, such as dapagliflozin and raltegravir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mefenamic AcidGlucuronosyltransferaseHeterocyclic Compounds, 2-RingPyrimidinesHumansAtazanavir SulfateDrug Interactions

Substanzen

vericiguatAtazanavir SulfateMefenamic AcidGlucuronosyltransferaseHeterocyclic Compounds, 2-RingPyrimidines

Autor:innen und Institutionen

  • Pharmacometrics/Modeling and Simulation, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
  • DMPK, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
  • Clinical Pharmacology, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Sebastian Frechen, André Dallmann, Michael Gerisch, Rolf Burghaus

Zitieren

APA

Frechen, S., Ince, I., Dallmann, A., Gerisch, M., Jungmann, N. A., Becker, C., Lobmeyer, M., Trujillo, M. E., Xu, S., Burghaus, R., & Meyer, M. (2024). Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13059

Vancouver

Frechen S, Ince I, Dallmann A, Gerisch M, Jungmann NA, Becker C, et al. Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13059

BibTeX
@article{Frechen2024,
  author = {Frechen, Sebastian and Ince, Ibrahim and Dallmann, André and Gerisch, Michael and Jungmann, Natalia A and Becker, Corina and Lobmeyer, Maximilian and Trujillo, Maria E and Xu, Shiyao and Burghaus, Rolf and Meyer, Michaela},
  title = {Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13059}
}
Kostenlos starten →